openPR Logo
Press release

Alzheimer's Disease Market Set To Witness Spells of Growth in the 7MM By 2032, DelveInsight

07-12-2022 03:00 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Alzheimer's Disease Market

Alzheimer's Disease Market

DelveInsight's Alzheimer's Disease Market report offers detailed information on current treatment practices, emerging drugs, Alzheimer's Disease market share of the individual therapies, current and forecasted Alzheimer's Disease market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Alzheimer's disease: An Overview
Alzheimer's disease is a debilitating neurological disorder that progressively mars the memory and cognitive flexibility and functioning of the brain. The patients find it difficult to perform daily routine things such as driving a car, preparing a meal, paying bills, or memorizing things. Alzheimer's disease is the most common cause of dementia, accounting for 60-80% of dementia cases.

Download a sample copy of the report @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Key highlights of the Alzheimer's disease Market Report
• According to a review article entitled "Alzheimer Disease" by Liana G. Apostolova et al., one nationally representative US data set, the Aging, Demographics, and Memory Study (ADAMS), estimated that in the United States, 14% of people of 71 years and older have dementia. Alzheimer's disease (AD) accounted for 70% of the dementia cases across the age spectrum in this cohort [2016].
• As per Shaheen E Lakhan et. al., according to a 2017 report, AD affects an estimated 6.08 million people in the US, and approximately 200,000 people younger than 65 years with AD constitute the younger-onset US population with AD [2019].
• According to Alzheimer's Association, more women than men have Alzheimer's or other dementias.

Alzheimer's disease Epidemiology Insights
Alzheimer's worsens over time. Alzheimer's is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage Alzheimer's, individuals lose the ability to carry on a conversation and respond to their environment. Alzheimer's is the sixth-leading cause of death in the United States. On average, a person with Alzheimer's lives 4-8 years after diagnosis, but can live as long as 20 years, depending on other factors.

Alzheimer's disease Epidemiology Segmentation in the 7MM
• Total Prevalent Cases
• Age-specific Prevalent Cases
• Gender-specific Prevalent Cases
• Diagnosed and Treatable Cases

Explore more information on the report @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Alzheimer's disease Market Insights
Alzheimer's disease attacks brain cells and neurotransmitters (chemicals that carry messages between brain cells), affecting the way brain functions, memory and behavior. It is also the most common form of dementia. There is no known cure for disease, and current approaches focus on helping people maintain mental function, manage behavioral symptoms, and slow down certain problems, such as memory loss. Two categories of drugs are approved for the treatment of Alzheimer disease: cholinesterase inhibitors and partial N-methyl D-aspartate (NMDA) antagonists.

Alzheimer's Disease Drugs Types
The U.S. Food and Drug Administration (FDA) has approved two types of medications - cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda) - to treat the cognitive symptoms (memory loss, confusion, and problems with thinking and reasoning) of Alzheimer's disease.

Alzheimer's disease Treatment Market
Currently, Alzheimer's is at the forefront of biomedical research. Researchers are working to uncover as many aspects of Alzheimer's disease and other dementias as possible. Some of the most remarkable progress has shed light on how Alzheimer's affects the brain. The hope is that better understanding will lead to new treatments. Many potential approaches are currently under investigation worldwide. Researchers hope to develop therapies targeting specific genetic, molecular, and cellular mechanisms so that the actual underlying cause of the disease can be stopped or prevented.

Request a sample copy of the report @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Alzheimer's Disease Market Dynamics
The dynamics of the Alzheimer's Disease (AD) market is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as Eisai Inc., Anavex Life Sciences Corp., etc. are involved in developing drugs for Alzheimer's Disease (AD).

Alzheimer's Disease Market Companies
• Shanghai Green Valley Pharmaceuticals
• Eisai Inc., and several others

Alzheimer's Disease Market Drugs
• Oligomannate
• BAN2401, and Several Others

Table of Content
1. Key Insights
2. Executive Summary of Alzheimer's Disease
3. Competitive Intelligence Analysis for Alzheimer's Disease
4. Alzheimer's Disease: Market Overview at a Glance
5. Alzheimer's Disease: Disease Background and Overview
6. Patient Journey
7. Alzheimer's Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Alzheimer's Disease Unmet Needs
10. Key Endpoints of Alzheimer's Disease Treatment
11. Alzheimer's Disease Marketed Products
12. Alzheimer's Disease Emerging Therapies
13. Alzheimer's Disease: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Alzheimer's Disease
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Connect with our Business Consultant @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting Services and Market research company, providing expert business solutions for the life science business development vertical and offering quintessential advisory services in the areas of R&D, Technical Due Diligence Firms, Strategy Formulation, Operations, Competitive Intelligence Pharma, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alzheimer's Disease Market Set To Witness Spells of Growth in the 7MM By 2032, DelveInsight here

News-ID: 2677811 • Views:

More Releases from DelveInsight Business Research

Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therapies from 10+ key Players, says DelveInsight
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therap …
According to DelveInsight's latest analysis, the global Spasticity pipeline features more than 10 active pharmaceutical companies that are advancing over 12 investigational therapies. The report offers a detailed evaluation of clinical trials, mechanisms of action, therapeutic approaches, routes of administration, and major developmental activities shaping the Spasticity treatment landscape. DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD 5.2 billion by 2032, analyses DelveInsight
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion by 2032, analyses DelveInsight
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billion by 2032, analyses DelveInsight
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced

All 5 Releases


More Releases for Alzheimer

Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928 Key Takeaways • Disease-modifying
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion. Data Bridge
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,